Linguamatics are delighted once more to sponsor the Findacure Student Voice Essay Competition. Findacure is a UK charity that is building the rare disease community to drive research and develop treatments.   

The winning essay will be published in the Orphanet Journal of Rare Diseases, and the essay topics are:

  1. The impact of a rare disease is much more widespread than its direct symptoms. Discuss how, with particular reference to the patient experience.
  2. How can rare diseases lead the way in medical research and clinical innovation?
  3. How can clinicians and researchers, including students, help to deliver the UK Strategy for Rare Diseases?

One of the big challenges for the development of treatments for rare disease is the need for a thorough understanding of the natural history of each of the 7000 currently known rare diseases. It’s critical to have detailed systematic information on both the genotypic aspect (the genes and mutations), and the phenotypic aspect (pathways involved or disrupted, symptom severities, etc.).


BOSTON, MA and NEW YORK, NY--(Marketwired - October 18, 2016) - Linguamatics, a world leader in NLP Text Mining, and Sinequa, a leader in Cognitive Search and Analytics, today announced a partnership based on a tight integration between I2E and Sinequa ES. This integration will provide life sciences and healthcare organizations with deeper insights from their ever-increasing volumes of enterprise unstructured textual data content across the entire enterprise.

Linguamatics' I2E text mining platform enhances the Sinequa Cognitive Search & Analytics platform with its advanced text mining capabilities, providing an unparalleled foundation to build upon in life sciences. The combined strength of both platforms helps users get more precise, actionable and contextual information in their field. They can ask questions such as "what treatments are used for breast cancer?" or "what diseases are treated by drug X?"


I recently attended a talk by Linguamatics CTO David Milward on Structured Queries for Unstructured Data, delivered to the Data Insights Cambridge Meetup group.

The data science community wants to know:

  • How can we deliver insights from big data?

  • What are the optimal approaches to ‘handle’ (store, capture) and analyze (query, structure, repurpose) big data?

The amount of data we can store and generate is many times what we could store or capture just 10 years ago. SQL Database technology is able to handle structured data well and has not changed significantly since the 1980s.  It’s easier to deliver insights from structured data for basic queries than it is for unstructured data in free text sources.

Unstructured data is the new frontier for data science

What drew so many people to David’s talk is the promise of the ‘data insights’ that are locked away in unstructured data. The audience spanned various industries, from those dealing with astronomical data to financial data sources, to many people concerned with health and life science unstructured data. Many industries rely heavily on data to inform their day to day business decisions. For healthcare and life science, where Linguamatics is the text mining leader, transforming how we understand and improve upon population health and patient outcomes will primarily entail extracting data insights from unstructured data sources. 


How ready are you for IDMP?

IDMP (IDentification of Medicinal Products) is a set of international standards developed by ISO that will become mandatory in Europe in a phased approach, effective from 2018, and will also be adopted by the FDA and globally over the next few years. As with any new regulatory change, it is valuable to hear about others' experiences and ideally understand and learn from industry best practice. 

Joining the IRISS Forum is the best way of keeping track of IDMP. I joined IRISS this year - it is an excellent source for up-to-date IDMP information and also valuable input from industry experts (such as Andrew Marr, Vada Perkins, and others).

The IRISS (Implementation of Regulatory Information Submission Standards) Forum was created to address the need for a single central forum for open and broad stakeholder discussion of evolving standards, user requirements and practical, global implementation issues of these standards for the mutual benefit of both industry, government agencies and ultimately, public health.

IRISS recently (September 2016) surveyed its members, both pharmaceutical and vendor, across the current state of readiness around IDMP compliance. The companies that took part in the industry survey covered a wide range of organizational sizes, from small companies those with less than 100 EU authorizations to larger ones with more than 5000 (or, less than 10 active ingredients to more than 250). Over 80% of those in the survey had a global reach. 

 


Drug safety and pharmacovigilance are critical aspects of drug development. To understand and monitor potential risks for pharmaceuticals, researchers use many different strategies to uncover evidence of real-world reports of adverse events and patient-reported outcomes.

At the upcoming Linguamatics Text Mining Summit, there are three talks on text mining strategies that improve our understanding of drug-related adverse reactions.

Nina Mian from AstraZeneca will present research on text mining adverse event data both from FDA drug labels (derived from clinical trial data), and also from real world data from PatientsLikeMe. Eric Lewis from GSK will discuss applications of I2E for clinical safety and pharmacovigilance – particularly the problems of identifying potential “new signals” and distinguishing signal from noise. And Stuart Murray from Agios will present workflows for automated identification of potential drug safety events.

These talks, from industry specialists, demonstrate the value of text mining to access and understand the complex world of drug safety and safety signals.